Previous 10 | Next 10 |
WALTHAM, Mass. , May 6, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter ended March 31, 2019 . In addition, the C...
WALTHAM, Mass. , April 29, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2019...
Thinly traded micro cap Syndax Pharmaceuticals ( SNDX -4.4% ) slips on below-average volume on the heels of updated results from a Phase 1b/2 clinical trial, ENCORE 601 , evaluating HDAC inhibitor entinostat plus Merck's ( MRK +0.1% ) Keytruda (pembrolizumab) in patients with solid tu...
WALTHAM, Mass. , April 1, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the presentation of updated findings from th...
Syndax Pharmaceuticals (NASDAQ: SNDX ) has entered into an agreement with Biotechnology Value Fund, L.P. ("BVF") and other investors for the purchase of 4.4M common stock at a price of $6.00/share, as well as warrants to purchase up to 2,183,331 and 2,183,335 common stock at an exerci...
WALTHAM, Mass. , March 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has entered into an agreement with Biotechnolo...
Noteworthy events during the week of March 24 - 30 for healthcare investors. More news on: Cidara Therapeutics, Inc., Recro Pharma, Inc., Autolus Therapeutics plc, Healthcare stocks news, , Read more ...
The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with this Read more ...
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2018 Results Earnings Conference Call March 07, 2019, 04:30 PM ET Company Participants Melissa Forst - Argot Partners, VP Briggs Morrison - CEO Richard Shea - CFO & Treasurer Michael Metzger - President & COO Michael Meyers - Chi...
Syndax Pharmaceuticals (NASDAQ: SNDX ): Q4 GAAP EPS of -$0.70 misses by $0.01 . More news on: Syndax Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Syndax Pharmaceuticals Inc. Company Name:
SNDX Stock Symbol:
NASDAQ Market:
Syndax Pharmaceuticals Inc. Website:
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia PR Newswire – New PDUFA action date of December 26, 2024 allows FDA additional time to complete their review – WALTHAM, Mass. , ...
Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024 PR Newswire WALTHAM, Mass. , July 25, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing...
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally...